Neoleukin Therapeutics Long Term Debt

As of the most recent data (June 2026), NLTX shows a long-term debt of $5.3M. That compares with $7.8M in the prior-year period — down 32.1% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, NLTX's long-term debt is now $5.3M (was $7.8M) — a 32.1% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Neoleukin Therapeutics is outperforming or lagging.

Tracking NLTX's long-term debt over time shows whether Neoleukin Therapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $5.3M That compares with $7.8M in the prior-year period — down 32.1% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this long-term debt page, Stockcircle has Neoleukin Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect long-term debt (currently $5.3M) with ownership activity and broader fundamentals.

Neoleukin Therapeutics's long-term debt is $5.3M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.